Genetic biomarkers in lung cancer therapy - an update

Biomarkers are objectively measured indicators of pathogenic processes of disease development or responses to a therapeutic intervention. It is commonly believed that development of reliable biomarkers for lung cancer both prognostic and predictive would considerably change disease diagnostics and treatment outcomes. Paper reviews current data on recent development in clinical applicability of molecular biomarkers in lung cancer.

Submit your paper

Archive

Instructions for authors

Send by email

Clinical immunology
Mediastinal lymphadenectomy causes immunosuppression after lung cancer surgery

Clinical immunology
Concentrations of interleukin 6 and interleukin 1 receptor antagonist in pleural fluid as early markers of complications after lung cancer surgery

Experimental immunology
Does the contamination of dendritic cells by lymphocytes skew the differentiation of monocytes into macrophages? A pilot study

Experimental immunology
The influence of the “bio-coat’s” type of culture dishes on the primary cultures of lung cancer cells

LAMA1 derived from colorectal cancer promotes M2 polarization in macrophages via activation of EGFR/AKT/CREB pathway

Indexes

Keywords index

Topics index

Authors index

We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).

You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.

I agree I do not agree

eISSN:	1644-4124
ISSN:	1426-3912